Table 1

 Baseline characteristics of patients

Knee OA (n = 914)Hip OA (n = 310)
*Non-steroidal anti-inflammatory drugs (before the start of the study); †other than NSAIDs (before the start of the study); ‡chondroitin sulphate, diacerhein, or avocado soybean unsaponifiables.
Age (years)67.810.265.710.8
Weight (kg)
Height (cm)163.68.7164.88.2
Body mass index (kg/m2)28.14.726.54.1
Disease duration (years)
Pain score (0–100 mm VAS)
    Week 058.316.956.717.4
    Change (week 0–week 4)−24.522.1−18.721.8
Patient global assessment (0–100 mm VAS)
    Week 058.719.158.616.5
    Change (week 0–week 4)−24.024.6−19.523.5
WOMAC function score (0–100)
    Week 042.916.645.917.1
    Change (week 0–week 4)−11.614.4−10.814.1
No (%) No (%)
Female sex637(69.7)189(61.0)
Kellgren and Lawrence grade
NSAID* intake during past 4 weeks262(28.8)97(31.3)
Analgesic intake†513(56.3)209(67.9)
Symptomatic slow acting drugs intake‡311(34.1)123(39.8)